Amgen IncNasdaq: AMGN

A Delaware jury on June 12, 2026 found that Amgen and subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld antibody discovery platform patent, awarding $20.2M in damages that could be trebled to roughly $60M given the willful finding. On June 16, Mizuho analyst Salim Syed maintained a Neutral rating on AMGN while raising his price target from $295 to $303, citing pipeline momentum. The European Commission had approved Amgen's Imdylltra for extensive-stage small cell lung cancer on June 1. Amgen also presented cardiometabolic data at the ADA Scientific Sessions on June 7. Risk: trebled damages and ongoing IP litigation could weigh on sentiment even though the dollar amount is modest relative to Amgen's $170B+ market cap.

Jury sides with Harbour BioMed in Amgen patent disputeiclg.comAMGN Maintains Rating by Mizuho -- Price Target Raised to $303gurufocus.comAmgen to present new data at EULAR 2026prnewswire.com

No material news in the last 48 hours.

No material news in the last 48 hours. Recent items (Morgan Stanley PT to $340, IMDYLLTRA/UPLIZNA approvals, Dark Blue Therapeutics acquisition, Tavneos hearing request) carry no clear date within the qualifying window.

No material news in the last 48 hours.

Amgen's price target was raised to $340 from $332 at Morgan Stanley in June 2026, while Bernstein maintained a Hold. The stock trades around $354.50 with a ~2.9% dividend yield. Recent pipeline catalysts are positive: Amgen reported positive topline Phase 3 results for subcutaneous Tepezza in moderate-to-severe active thyroid eye disease (April), landmark VESALIUS-CV cardiovascular outcomes for Repatha (cutting first major CV events by 31% in high-risk patients), and full FDA approval of IMDELLTRA in extensive-stage small cell lung cancer. The company also announced an additional $300M US manufacturing investment (~$2B over the past year) and acquired Dark Blue Therapeutics to bolster oncology. The key overhang is a potential FDA withdrawal of Tavneos, a regulatory risk to watch.

Press Releases | Amgen Inc.investors.amgen.comAmgen Inc. (AMGN) Latest Stock News & Headlinesfinance.yahoo.comAMGN: Amgen Inc - Stock Price, Quote and Newscnbc.com

Amgen on May 19, 2026 announced CFO Peter Griffith will retire effective August 31, 2026 after holding the role since 2020. Thomas Dittrich joins as EVP July 1 and becomes CFO from September 1. Griffith remains as a non-officer EVP through January 2027 for handover. Shareholders today reaffirmed the board, pay and auditors. The company advanced its Xaluritamig trial in hard-to-treat prostate cancer. Stock opened $323.25 with market cap of $178.5B and a 3.05% dividend yield. Annual revenue grew 12.3% with 27.7% FCF margin, though Tavneos faces safety scrutiny in Japan.

Amgen CFO Transition - TipRankstipranks.comAmgen Manufacturing Investment - Amgen Newsroomamgen.com

On May 19, 2026, Amgen announced that EVP and CFO Peter Griffith, who has held the CFO role since 2020, will retire effective August 31, 2026 and remain in a non-officer EVP role through January 2027 for transition. Thomas Dittrich, a veteran finance executive with prior senior Amgen roles and CFO experience at Galderma, Shire, and Sulzer, will join as EVP effective July 1, 2026 and become CFO on September 1, 2026. Separately on May 4, Amgen announced an additional $300M U.S. manufacturing investment, bringing the total to nearly $2B over the past year, with capacity growth in Puerto Rico. Q1 2026 results posted earlier included $8.62B revenue and adjusted EPS of $5.15, with raised full-year guidance of $37.1-$38.5B revenue. Risk: Erste Group downgraded AMGN to Hold citing sales-growth deceleration risk in 2026-2027.

Amgen Announces CFO Transition and Leadership Succession Plantipranks.comAmgen Announces Additional $300 Million U.S. Manufacturing Investmentamgen.comAmgen Reports First Quarter 2026 Financial Resultsamgen.com

Amgen announced an additional $300 million investment in US manufacturing on May 12, 2026, bringing total US capex commitments to nearly $2 billion over the past year, including a Puerto Rico biologics facility expansion. CFO Peter Griffith and R&D head Jay Bradner presented at the BofA Global Healthcare Conference on May 13. Erste Group's Hans Engel downgraded AMGN to Hold from Buy, citing expected sales growth deceleration in 2026-2027. Q1 2026 results beat with $8.62B revenue and $5.15 adjusted EPS, and management raised full-year guidance to $37.1-$38.5B revenue and $21.70-$23.10 non-GAAP EPS. Risks include continued safety concerns around Tavneos and biosimilar pressure. Sentiment is mixed.

Amgen Announces Additional $300 Million U.S. Manufacturing Investmentamgen.comAmgen to Present at the Bank of America Merrill Lynch Global Healthcare Conferenceamgen.comAmgen Inc. stockad-hoc-news.de

No material news in the last 48 hours.

Amgen reported Q1 2026 revenue of $8.62B (+5.8% YoY, 0.5% above consensus) with adjusted EPS of $5.15 vs $4.77 expected. The company raised 2026 guidance and hiked its quarterly dividend 6% to $2.52 per share. Amgen announced an additional $300M investment in Puerto Rico to expand its US manufacturing network. Pipeline highlights include MariTide for obesity/type 2 diabetes, strong Phase III data for subcutaneous Tepezza, and multiple bispecific T-cell engagers for oncology. However, Piper Sandler lowered its price target citing a weaker rare disease outlook. Analyst consensus is Hold (19 analysts) with an avg 12-month PT of $350.89 (8.4% upside). Risk: patent expirations and biosimilar competition remain a concern; 2026 is framed as a "springboard year" where growing products must offset patent cliff impact.

A Look At Amgen (AMGN) Valuation After Q1 Beat Guidance Upgrade And US$300 Million US Expansionsimplywall.stPiper Sandler lowers Amgen stock price target on rare disease outlookinvesting.comEarnings call transcript: Amgen Q1 2026 beats EPS forecast, stock dipsinvesting.com

On May 4, 2026, Amgen disclosed an additional $300 million investment in its U.S. manufacturing network, primarily expanding its Puerto Rico biologics facility, bringing total announced U.S. investments to nearly $2 billion over the past year (including $650M in Puerto Rico, $900M in Ohio, $600M in California). CFO Peter Griffith and EVP R&D Jay Bradner are scheduled to present at the Bank of America Merrill Lynch Global Healthcare Conference on May 13, 2026. The ex-dividend date for the quarterly $2.52 dividend is May 15, 2026. The investment supports advanced manufacturing capacity and strengthens domestic supply chain resilience. Despite a Q1 beat and raised 2026 guidance ($37.1B-$38.5B revenue, $21.70-$23.10 non-GAAP EPS), shares trade around $336 with concerns about patent cliffs. Risk: heavy capex may pressure near-term margins, and patent expirations remain an overhang on the Hold-rated stock.

Amgen Announces Additional $300 Million U.S. Manufacturing Investmentamgen.comAmgen May 13 healthcare conference webcast setstocktitan.netAmgen's New Puerto Rico Biologics Investment - Simply Wall Stsimplywall.st

Amgen announced on May 4, 2026, an additional $300 million U.S. manufacturing investment, bringing total commitments to nearly $2 billion over the past year. The expansion includes a Puerto Rico biologics manufacturing facility to support workforce development and hundreds of construction jobs. In early May, Amgen reported Q1 2026 results with revenue of $8.618 billion and net income of $1.819 billion. Management raised FY2026 revenue guidance to $37.1-$38.5 billion and non-GAAP EPS to $21.70-$23.10, backed by 9% volume growth and 16 brands with double-digit sales increases. Senior leadership changes emphasized AI and data as core to operations. CFO Peter Griffith and R&D EVP Jay Bradner present at Bank of America Healthcare Conference on May 13.

Amgen Announces Additional $300 Million U.S. Manufacturing Investmentamgen.comAmgen raises 2026 guidance to $37.1B-$38.5B revenueseekingalpha.comAmgen to Present at Bank of America Merrill Lynch Global Healthcare Conferenceamgen.com

Amgen disclosed a new $300 million investment in its U.S. manufacturing network, bringing total commitments to nearly $2 billion over the past year, with a focus on expanding its Puerto Rico biologics facility. The company also confirmed its CFO Peter Griffith and R&D head Jay Bradner will present at the BofA Merrill Lynch Global Healthcare Conference on May 13, 2026. This follows Amgen's recent raise of full-year 2026 guidance to $37.1B-$38.5B in revenue and $21.70-$23.10 non-GAAP EPS, driven by 9% volume growth across 16 brands with double-digit sales gains. Management is emphasizing AI and data integration as core to future operations. Risks include biosimilar competition and pricing pressure. Consensus analyst rating remains Hold.

Amgen Announces Additional $300 Million U.S. Manufacturing Investmentamgen.comAmgen May 13 healthcare conference webcast setstocktitan.netAmgen raises 2026 guidance to $37.1B-$38.5B revenueseekingalpha.com